Capicua suppresses YAP1 to limit tumorigenesis and maintain drug sensitivity in human cancer

Cell Rep. 2022 Oct 4;41(1):111443. doi: 10.1016/j.celrep.2022.111443.

Abstract

Inactivation of Capicua (CIC) or upregulation of yes-associated protein 1, YAP1, leads to broad RAS-RAF-MEK-ERK inhibitor resistance and tumor progression in multiple human cancers. Despite these shared malignant phenotypes, it remains unclear whether CIC and YAP1 are mechanistically linked. Here, we show that the ERK-regulated transcription factor CIC can directly repress YAP1 expression through non-consensus GGAAGGAA DNA-binding motifs in a proximal YAP1 regulatory element. Through binding at GGAA repeats, CIC regulates YAP1 transcriptional output in both normal and human cancer cells. Silencing YAP1 in CIC-deficient cells restores MAPK inhibitor sensitivity and suppresses tumor growth. Thus, we uncover a molecular link between the MAPK-ERK effector CIC and YAP1 in human cells and established YAP inhibition as a strategy to target CIC-deficient cancers.

Keywords: CIC; CP: Cancer; CP: Molecular biology; Capicua; MAPK inhibitor resistance; YAP1.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Carcinogenesis / genetics
  • Cell Line, Tumor
  • Cell Transformation, Neoplastic / genetics
  • DNA
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Mitogen-Activated Protein Kinase Kinases / metabolism
  • Neoplasms* / drug therapy
  • Neoplasms* / genetics
  • Repressor Proteins* / metabolism
  • Transcription Factors / metabolism
  • YAP-Signaling Proteins

Substances

  • CIC protein, human
  • Repressor Proteins
  • Transcription Factors
  • YAP-Signaling Proteins
  • YAP1 protein, human
  • DNA
  • Mitogen-Activated Protein Kinase Kinases